Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters Corporation (NYSE:WAT) has launched the Waters Arc Premier System, the first liquid chromatography system designed for 2.5 – 3.5 micron columns featuring MaxPeak High Performance Surface (HPS) technology. This system reduces analyte-surface interactions, thereby improving analytical results for laboratories. Benefits include increased sensitivity, reproducibility, and potential savings of 2-3 days per assay by eliminating passivation. The combination of the Arc Premier System and MaxPeak Premier Columns aims to enhance productivity, accuracy, and confidence in pharmaceutical analysis.
Waters Corporation (NYSE:WAT) has launched the Waters™ SELECT SERIES™ MRT, an advanced mass spectrometer integrating Multi Reflecting Time-of-Flight (MRT) technology with enhanced DESI and new MALDI imaging sources. This device allows for rapid, precise identification of molecules, achieving speeds of up to 10Hz without losing mass accuracy. The SELECT SERIES MRT boasts a resolution of 200,000 FWHM, setting a new standard in mass spectrometry. Shipments are slated to begin in Q4 of this year, promising significant advancements in biological research and imaging applications.
Waters Corporation (NYSE:WAT) has launched a new RUO LC-MS test method, the SARS-CoV-2 LC-MS Kit, to enhance infectious disease research. This innovative method allows for the direct detection and quantification of SARS-CoV-2 Nucleocapsid (NCAP) peptides, yielding highly accurate results. Developed in collaboration with various research entities, this method aims to support high-throughput screening with reduced reliance on PCR reagents. The kit can quantify low levels of NCAP peptides, facilitating impactful studies on infection stages and future pandemic preparedness.
Summary not available.
Waters Corporation (NYSE: WAT) reported first quarter 2021 sales of $609 million, up 31% from $465 million in Q1 2020. EPS rose to $2.37 (GAAP) from $0.86 yoy. Net cash from operations reached $218 million, an increase from $152 million. Instrument sales grew 49%, with pharmaceutical sales up 32%. The company anticipates full-year 2021 constant-currency sales growth of 8% to 11% and non-GAAP EPS of $9.85 to $10.05. The Q1 earnings call is scheduled for May 5, 2021.
Waters Corporation (NYSE:WAT) will present at the Bank of America Securities 2021 Virtual Health Care Conference on May 12, 2021, at 2:00 PM EST. CEO Udit Batra will address the investment community, discussing the company’s innovations in chromatography and mass spectrometry that have served the life sciences for over 60 years. Waters, a leader in specialty measurement, has a global workforce of 7,400 and operates in 35 countries.
Waters Corporation (NYSE: WAT) announced significant leadership changes as part of its transformation program. Amol Chaubal will become the new CFO on May 12, 2021, bringing extensive financial experience from Quanterix Corporation. Michael Silveira resumes his role as Corporate Controller. Retirements for Dr. Mike Harrington and Ian King will take effect on July 2, 2021. The company has established an Innovation Board to enhance R&D collaboration. Jonathan Pratt and Jianqing Bennett have been appointed in key positions, aiming to drive growth and innovation.
Waters Corporation (NYSE:WAT) and Genovis AB are partnering to create automated biopharmaceutical characterization workflows using Waters' BioAccord LC-MS System, Andrew+ pipetting robot, and Genovis' SmartEnzymes. This collaboration aims to improve the speed and consistency of analytical processes involving monoclonal antibodies and protein-based drugs. By integrating automation and advanced enzyme technology, they target enhancements in quality control and bioprocess development, addressing significant bottlenecks in current biologics analysis.
Waters Corporation (NYSE:WAT) will webcast its Q1 2021 financial results conference call on May 5, 2021, at 8:00 a.m. ET. Interested parties can access the live broadcast via the Waters website. The company, a leader in specialty measurement, has over 7,400 employees across 35 countries and has been a pioneer in chromatography and mass spectrometry for over 60 years. A replay of the conference call will be available until May 12, 2021.
Waters Corporation (NYSE: WAT) has unveiled a new peptide multi-attribute method (MAM) workflow for its BioAccord™ LC-MS System. This innovation allows scientists in drug development and QC to efficiently monitor the efficacy and safety of monoclonal antibodies and protein-based drugs. The workflow enhances the analysis of critical quality attributes (CQAs), including product variants and impurities, improving decision-making in manufacturing. This system aims to democratize mass spectrometry use by making it accessible to scientists with limited experience.